Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers

C. P. Jonescu-Cuypers, Alon Harris, Y. Ishii, L. Kagemann, H. J. Gazozi, Y. Rotenstreich, Sung Chung Hak Sung Chung, B. Martin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

While α2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic α2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow. Consequently, the ocular hemodynamic effects of brimonidine were studied in normal subjects. Twelve healthy volunteers were included in this prospective, double-masked, placebo controlled, crossover-designed clinical trial. They received either brimonidine tartrate 0.2% or placebo b.i.d. for 2 weeks. Goldmann tonometry and color Doppler imaging (CDI) were performed at baseline, at 2 hr, 1 week, and 2 weeks after the treatment. Fundus angiography using a scanning laser ophthalmoscope was performed at baseline and 2 weeks after treatment to determine retinal arteriovenous passage time. Brimonidine lowered IOP at 2 hr, 1 week, and 2 weeks (p = 0.058, p = 0.031, and p = 0.022, respectively). Brimonidine did not affect the retrobulbar arterial velocities measured by CDI, nor retinal arteriovenous passage time. In conclusion, two-week treatment with brimonidine reduces IOP and does not reduce the bulk retinal or retrobulbar arterial perfusion in young healthy volunteers.

Original languageEnglish
Pages (from-to)199-205
Number of pages7
JournalJournal of Ocular Pharmacology and Therapeutics
Volume17
Issue number3
StatePublished - 2001

Fingerprint

Healthy Volunteers
Hemodynamics
Intraocular Pressure
Color
Placebos
Ophthalmoscopes
Adrenergic Agonists
Manometry
Vasoconstrictor Agents
Brimonidine Tartrate
Vascular Smooth Muscle
Angiography
Lasers
Therapeutics
Perfusion
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Jonescu-Cuypers, C. P., Harris, A., Ishii, Y., Kagemann, L., Gazozi, H. J., Rotenstreich, Y., ... Martin, B. (2001). Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. Journal of Ocular Pharmacology and Therapeutics, 17(3), 199-205.

Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. / Jonescu-Cuypers, C. P.; Harris, Alon; Ishii, Y.; Kagemann, L.; Gazozi, H. J.; Rotenstreich, Y.; Hak Sung Chung, Sung Chung; Martin, B.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 3, 2001, p. 199-205.

Research output: Contribution to journalArticle

Jonescu-Cuypers, CP, Harris, A, Ishii, Y, Kagemann, L, Gazozi, HJ, Rotenstreich, Y, Hak Sung Chung, SC & Martin, B 2001, 'Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers', Journal of Ocular Pharmacology and Therapeutics, vol. 17, no. 3, pp. 199-205.
Jonescu-Cuypers CP, Harris A, Ishii Y, Kagemann L, Gazozi HJ, Rotenstreich Y et al. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. Journal of Ocular Pharmacology and Therapeutics. 2001;17(3):199-205.
Jonescu-Cuypers, C. P. ; Harris, Alon ; Ishii, Y. ; Kagemann, L. ; Gazozi, H. J. ; Rotenstreich, Y. ; Hak Sung Chung, Sung Chung ; Martin, B. / Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. In: Journal of Ocular Pharmacology and Therapeutics. 2001 ; Vol. 17, No. 3. pp. 199-205.
@article{769c1ae4009d4309816575405ea36516,
title = "Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers",
abstract = "While α2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic α2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow. Consequently, the ocular hemodynamic effects of brimonidine were studied in normal subjects. Twelve healthy volunteers were included in this prospective, double-masked, placebo controlled, crossover-designed clinical trial. They received either brimonidine tartrate 0.2{\%} or placebo b.i.d. for 2 weeks. Goldmann tonometry and color Doppler imaging (CDI) were performed at baseline, at 2 hr, 1 week, and 2 weeks after the treatment. Fundus angiography using a scanning laser ophthalmoscope was performed at baseline and 2 weeks after treatment to determine retinal arteriovenous passage time. Brimonidine lowered IOP at 2 hr, 1 week, and 2 weeks (p = 0.058, p = 0.031, and p = 0.022, respectively). Brimonidine did not affect the retrobulbar arterial velocities measured by CDI, nor retinal arteriovenous passage time. In conclusion, two-week treatment with brimonidine reduces IOP and does not reduce the bulk retinal or retrobulbar arterial perfusion in young healthy volunteers.",
author = "Jonescu-Cuypers, {C. P.} and Alon Harris and Y. Ishii and L. Kagemann and Gazozi, {H. J.} and Y. Rotenstreich and {Hak Sung Chung}, {Sung Chung} and B. Martin",
year = "2001",
language = "English",
volume = "17",
pages = "199--205",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers

AU - Jonescu-Cuypers, C. P.

AU - Harris, Alon

AU - Ishii, Y.

AU - Kagemann, L.

AU - Gazozi, H. J.

AU - Rotenstreich, Y.

AU - Hak Sung Chung, Sung Chung

AU - Martin, B.

PY - 2001

Y1 - 2001

N2 - While α2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic α2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow. Consequently, the ocular hemodynamic effects of brimonidine were studied in normal subjects. Twelve healthy volunteers were included in this prospective, double-masked, placebo controlled, crossover-designed clinical trial. They received either brimonidine tartrate 0.2% or placebo b.i.d. for 2 weeks. Goldmann tonometry and color Doppler imaging (CDI) were performed at baseline, at 2 hr, 1 week, and 2 weeks after the treatment. Fundus angiography using a scanning laser ophthalmoscope was performed at baseline and 2 weeks after treatment to determine retinal arteriovenous passage time. Brimonidine lowered IOP at 2 hr, 1 week, and 2 weeks (p = 0.058, p = 0.031, and p = 0.022, respectively). Brimonidine did not affect the retrobulbar arterial velocities measured by CDI, nor retinal arteriovenous passage time. In conclusion, two-week treatment with brimonidine reduces IOP and does not reduce the bulk retinal or retrobulbar arterial perfusion in young healthy volunteers.

AB - While α2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic α2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow. Consequently, the ocular hemodynamic effects of brimonidine were studied in normal subjects. Twelve healthy volunteers were included in this prospective, double-masked, placebo controlled, crossover-designed clinical trial. They received either brimonidine tartrate 0.2% or placebo b.i.d. for 2 weeks. Goldmann tonometry and color Doppler imaging (CDI) were performed at baseline, at 2 hr, 1 week, and 2 weeks after the treatment. Fundus angiography using a scanning laser ophthalmoscope was performed at baseline and 2 weeks after treatment to determine retinal arteriovenous passage time. Brimonidine lowered IOP at 2 hr, 1 week, and 2 weeks (p = 0.058, p = 0.031, and p = 0.022, respectively). Brimonidine did not affect the retrobulbar arterial velocities measured by CDI, nor retinal arteriovenous passage time. In conclusion, two-week treatment with brimonidine reduces IOP and does not reduce the bulk retinal or retrobulbar arterial perfusion in young healthy volunteers.

UR - http://www.scopus.com/inward/record.url?scp=0034951857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034951857&partnerID=8YFLogxK

M3 - Article

C2 - 11436940

AN - SCOPUS:0034951857

VL - 17

SP - 199

EP - 205

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -